Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

IBI3001 hos deltakere med uoperable, lokalt avanserte eller metastatiske solide svulster

22. september 2026 oppdatert av: Fortvita Biologics (USA)Inc.

En fase 1/2-studie av IBI3001 hos deltakere med uoperable, lokalt avanserte eller metastatiske solide svulster

This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

250

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
      • Wollongong, New South Wales, Australia, 2500
    • South Australia
      • Adelaide, South Australia, Australia, 5000
    • California
      • Los Angeles, California, Forente stater, 90025
    • New Jersey
      • East Brunswick, New Jersey, Forente stater, 08816
    • Texas
      • Dallas, Texas, Forente stater, 75039
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Aktiv, ikke rekrutterende
        • Virginia Cancer Specialists
    • Anhui
      • Hefei, Anhui, Kina, 230022
        • Rekruttering
        • The First Affiliated Hospital of Anhui Medical University
        • Ta kontakt med:
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100021
        • Rekruttering
        • Cancer Hospital, Chinese Academy of Medical Sciences
        • Ta kontakt med:
      • Beijing, Beijing Municipality, Kina, 100853
        • Rekruttering
        • Chinese People's Liberation Army General Hospital
        • Ta kontakt med:
    • Fujian
      • Fuzhou, Fujian, Kina, 350014
      • Fuzhou, Fujian, Kina, 350005
        • Rekruttering
        • First Affiliated Hospital, Fujian Medical University
        • Ta kontakt med:
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Rekruttering
        • The Affiliated Tumor Hospital of Guangxi Medical University
        • Ta kontakt med:
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150081
        • Rekruttering
        • Harbin Medical University Cancer Hospital
        • Ta kontakt med:
    • Henan
      • Anyang, Henan, Kina, 455100
      • Luoyang, Henan, Kina, 471003
        • Rekruttering
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Ta kontakt med:
      • Zhengzhou, Henan, Kina, 450008
      • Zhengzhou, Henan, Kina, 450052
        • Rekruttering
        • The First Affiliated Hospital of Zhengzhou University
        • Ta kontakt med:
    • Hubei
      • Wuhan, Hubei, Kina, 430022
        • Rekruttering
        • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Ta kontakt med:
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Rekruttering
        • Xiangya Hospital, Central South University
        • Ta kontakt med:
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210008
        • Rekruttering
        • Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
        • Ta kontakt med:
      • Nanjing, Jiangsu, Kina, 210029
        • Rekruttering
        • Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
        • Ta kontakt med:
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330029
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200120
        • Rekruttering
        • Shanghai East Hospital, Tongji University School of Medicine
        • Ta kontakt med:
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • West China Hospital, Sichuan University
        • Ta kontakt med:
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • Sichuan Cancer Hospital & Institute
        • Ta kontakt med:
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310022
      • Hangzhou, Zhejiang, Kina, 310003
        • Rekruttering
        • The First Affiliated Hospital, Zhejiang University School of Medicine
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  1. Male or female participants ≥ 18 years old;
  2. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
  3. Has an anticipated life expectancy of ≥ 12 weeks;
  4. Adequate bone marrow and organ function:
  5. At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
  6. Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.

Key Exclusion Criteria:

  1. Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
  2. Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
  3. Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
  4. Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
  5. Known symptomatic central nervous system (CNS) metastases.
  6. History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
  7. History of endotracheal or gastrointestinal stent implantation;
  8. Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
  9. Esophageal or gastric varices requiring immediate intervention;
  10. Not eligible to participate in this study at the discretion of the investigator;
  11. Do not have adequate treatment washout period before study drug administration. -

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Åpen etikett: IBI3001 monoterapi

The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.

IBI3001 is proposed to be administered by intravenous infusion (IV)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of subjects with adverse events
Tidsramme: 24 months

Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria

24 months
Number of subjects with clinically significant changes in physical examination results
Tidsramme: 24 months

Clinically significant abnormal physical examination findings reported by the investigator.

24 months
Number of subjects with clinically significant changes in vital signs
Tidsramme: 24 months

Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure

24 months
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
Tidsramme: 24 months

Dose limiting toxicity (DLT) to establish MTD or RP2D

24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Plasma concentration (Cmax) of IBI3001
Tidsramme: 24 months

Plasma concentration of IBI3001 for single and multiple doses.

24 months
Area under the curve (AUC) of IBI3001
Tidsramme: 24 months

AUC of IBI3001 for single and multiple doses

24 months
Time to maximum concentration (Tmax) of IBI3001
Tidsramme: 24 months

Tmax of IBI3001 for single and multiple doses.

24 months
Clearance (CL) of IBI3001
Tidsramme: 24 months

Clearance of IBI3001 from the plasma

24 months
Volume of distribution (V) of IBI3001
Tidsramme: 24 months

Apparent volume of distribution of IBI3001

24 months
Half-life (T1/2) of IBI3001
Tidsramme: 24 months

T1/2 of IBI3001 for single and multiple doses

24 months
Immunogenicity of IBI3001
Tidsramme: 24 months

Incidence of anti-drug (IBI3001) antibody

24 months
Objective response rate (ORR)
Tidsramme: 24 months

ORR as evaluated per the RECIST v1.1 criteria

24 months
Duration of response (DoR)
Tidsramme: 24 months

DoR as evaluated per the RECIST v1.1 criteria

24 months
Disease control rate (DCR)
Tidsramme: 24 months

DCR as evaluated per the RECIST v1.1 criteria

24 months
Time to response (TTR)
Tidsramme: 24 months

TTR as evaluated per the RECIST v1.1 criteria

24 months
Progression free survival (PFS)
Tidsramme: 24 months

PFS as evaluated per the RECIST v1.1 criteria

24 months
Overall survival (OS)
Tidsramme: 24 months

Overall survival.

24 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. januar 2025

Primær fullføring (Antatt)

31. desember 2026

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

1. april 2024

Først innsendt som oppfylte QC-kriteriene

1. april 2024

Først lagt ut (Faktiske)

5. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

25. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CIBI3001A101

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere